CYTH Profile
Cyclo Therapeutics, Inc., a clinical-stage biotechnology firm, is at the forefront of developing innovative cyclodextrin-based therapeutics for a range of diseases. The company's flagship drug candidate, Trappsol Cyclo, is currently undergoing Phase III clinical trials for the treatment of Niemann-Pick Type C disease, a rare and progressive genetic disorder. In addition to its work in rare diseases, Cyclo Therapeutics is also exploring the potential of Trappsol Cyclo in addressing Alzheimer's disease, aiming to leverage its cyclodextrin technology to improve patient outcomes in neurodegenerative conditions.
Beyond its drug development efforts, Cyclo Therapeutics engages in the commercialization of cyclodextrins and related products for various applications. These cyclodextrin-based products are utilized across the pharmaceutical, nutritional, and diagnostic industries, where they serve critical roles in enhancing drug delivery, stabilizing compounds, and enabling specialty diagnostic assays. The company's expertise in cyclodextrin chemistry supports its broad product portfolio and its ability to address diverse industry needs.
The company’s business model integrates both its drug development pipeline and its commercial cyclodextrin products, providing a comprehensive approach to advancing cyclodextrin technology in therapeutic and industrial applications. Cyclo Therapeutics' commitment to innovation and research is underscored by its strategic focus on developing treatments for unmet medical needs and improving therapeutic efficacy through cyclodextrin-based formulations.
Founded in 1990 and headquartered in Gainesville, Florida, Cyclo Therapeutics, Inc. was previously known as CTD Holdings, Inc. The company rebranded to Cyclo Therapeutics, Inc. in September 2019 to better reflect its focus on developing cutting-edge cyclodextrin-based therapies. With a robust pipeline and a strong commercial presence, Cyclo Therapeutics continues to advance its mission of transforming treatment paradigms and improving lives through cyclodextrin technology.
|
